NOS2 and metastatic neoplasm: We wanted to study whether the density of iNOS+ M1-like macrophages in the IM or CT combined with CD8+ T-cells in the CT would predict the length of trastuzumab free-periods in metastatic disease better than CD8+ T-cells alone.